Summary
All the experimental animal models of insulin-dependent diabetes mellitus (IDDM) and preliminary human trials suggest that insulin can be safely used not only for immediate therapeutic purposes but also in the prevention of the disease. The mechanism of protection induced by insulin prophylaxis may include both ‘β-cell rest’ and induction of immunoregulatory processes. Finally, combined therapies involving oral, subcutaneous and intravenous routes may be of potential advantage in disease prevention. Future studies will have to address these issues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baekkeskov S, Aanstoot HJ, Christgau S, et al. The 64kD autoantigen in insulin-dependent diabetes is the GABA synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151–6
Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337–9
Riley WJ, Maclaren NK, Krischer JP, et al. A prospective study of the development of diabetes in relatives of patients with insulin dependent diabetes. N Engl J Med 1990; 323: 1167–72
Krischer JP, Schatz D, Riley WJ, et al. Insulin and islet cell autoantibodies as time dependent covariates in the development of insulin dependent diabetes: a prospective study in relatives. J Clin Endocrinol Metab 1993; 77(3): 743–9
Keller RJ. Cellular immunity to human insulin in individuals at high risk for the development of type 1 diabetes mellitus. J Autoimmunity 1990; 3: 321–7
Portha B, Picon L. Insulin treatment improves the spontaneous remission of neonatal streptozotocin diabetes in the rat. Diabetes 1982; 31: 165–9
Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933–5
Atkinson M, Maclaren N, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39(8): 933–7
Thivolet CH, Goillet E, Bedossa P, et al. Insulin prevents adoptive cell transfer of diabetes in the autoimmune non-obese diabetic mouse. Diabetologia 1991; 34: 314–9
Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927–8
Kämpe O, Andersson A, Björk E, et al. High glucose stimulation of 64000 Mislet cell autoantigen expression. Diabetes 1989; 38: 1326–8
Hagopian WA, Karlson AE, Peterson JS, et al. Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 1993; 132: 2674–81
Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155–7
Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced secretion. Diabetes Care 1992; 15: 442–55
Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T cell self tolerance to glutamate decarboxylase is a key event in the pathogenesis of murine insulin-dependent diabetes. Nature 1993; 366: 69–71
Mabsbad S. Factors of importance for residual beta-cell function in type I diabetes mellitus: a review. Acta Med Scand Suppl. 1983; 671: 61–7
Perlman K, Ehrlich RM, Filler RM, et al. Sustained normoglycemia in newly diagnosed type 1 diabetic subjects: short term effects and one year follow-up. Diabetes 1984; 33: 995–1001
Shah S, Malone J, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin dependent diabetes mellitus. N Engl J Med 1989; 320: 540–4
Anon. Diabetes Prevent Ther 1993; 7: 8
Rodrigues Villar C, Vidal J, Gonzalez-Clemente JM, et al. Insulin, beta cell rest and high risk of type 1 diabetes mellitus [letter]. Lancet 1993; 341: 1291
Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257: 1130–4
Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321–4
Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727–30
Zhang I, Davidson L, Eisenbarth G, et al. Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88: 10252–6
Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809–37
Muir A, Schatz D, Maclaren N. Antigen specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 1993; 9(4): 279–87
Friedman A, Weiner HL. Induction of anergy and/or active suppression in oral tolerance is determined by frequency of feeding and antigen dosage. J Immunol 1993; 150: 4A
Miller A, Lider O, Roberts, AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein both in vitro and in vivo: immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89: 421–5
Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes 1994; 43: 613–21
Muir A, Peck A, Clare-Salzler M, et al. Insulin immunization of NOD mice diminished intra-islet interferon-transcription. J Clin Invest. In press
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ramiya, V., Muir, A. & Maclaren, N.K. Insulin Prophylaxis in Insulin-Dependent Diabetes Mellitus. Clin. Immunother. 3, 177–183 (1995). https://doi.org/10.1007/BF03259053
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259053